Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes  

作　　者：Angeliki Bourazana Grigorios Giamouzis John Skoularigis Filippos Triposkiadis Andrew Xanthopoulos 

机构地区：[1]Department of Cardiology,University Hospital of Larissa,Larissa 41110,Greece

出　　处：《World Journal of Cardiology》2022年第4期266-270,共5页世界心脏病学杂志（英文版）（电子版）

摘　　要：Diabetes mellitus(DM)is a health condition characterized by glucose dysregulation and affects millions of people worldwide.The presentation of heart failure in diabetic cardiomyopathy extends over a wide phenotypic spectrum,commencing from asymptomatic,subclinical structural abnormalities to severely symptomatic biventricular dysfunction with increased mortality risk.Similarly,the spectrum of systolic dysfunction in diabetic-induced heart failure is diverse.DM leads also to cardiac electrical remodeling reacting on various targets.Dipeptidyl peptidase-4(DPP-4)inhibitors reduce glucagon and blood glucose levels by raising levels of the endogenous hormones glucagon-like-peptide 1 and glucose-dependent insulinotropic peptide and constitute a safe and effective glucose lowering treatment option in patients with type 2 DM.Despite DPP-4 inhibitors’efficacy regarding glycemic control,their effect on cardiovascular outcomes(myocardial infarction,stroke,hospitalization for heart failure,hospitalization for unstable angina,hospitalization for coronary revascularization,and cardiovascular death)in diabetic patients has been neutral.The potential correlation between atrial flutter and DPP-4 inhibitors administration needs further investigation.

关 键 词：Dipeptidyl peptidase-4 inhibitors Diabetes mellitus OUTCOMES Metaanalysis Heart failure Atrial flutter 

分 类 号：R587.1[医药卫生—内分泌]